ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year

blonca9
Dec 10, 2024
1 min read

CMO Gianfranco Pittari describes the unmet neet in GvHD and how the donor derived microbiome treatment is designed to work. A patient has also been treated at City of Hope in the United States.

Recent Posts

See All

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight